Research programme: therapeutics - Gmax Biopharm
Latest Information Update: 28 Apr 2024
At a glance
- Originator Gmax Biopharm
- Class Analgesics; Antihyperglycaemics; Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders; Osteoporosis; Pain
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Metabolic-disorders in China
- 28 Apr 2024 No recent reports of development identified for research development in Osteoporosis in China
- 28 Apr 2024 No recent reports of development identified for research development in Pain in China